Lyra Therapeutics (LYRA) Competitors $6.89 +0.11 (+1.62%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.89 0.00 (0.00%) As of 06:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. MODD, ZYXI, NMTC, TMDIF, NEPH, POCI, PSTV, PYPD, COCH, and VVOSShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Modular Medical (MODD), Zynex (ZYXI), NeuroOne Medical Technologies (NMTC), Titan Medical (TMDIF), Nephros (NEPH), Precision Optics (POCI), Plus Therapeutics (PSTV), PolyPid (PYPD), Envoy Medical (COCH), and Vivos Therapeutics (VVOS). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. Its Competitors Modular Medical Zynex NeuroOne Medical Technologies Titan Medical Nephros Precision Optics Plus Therapeutics PolyPid Envoy Medical Vivos Therapeutics Modular Medical (NASDAQ:MODD) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Is MODD or LYRA more profitable? Modular Medical has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,711.39%. Modular Medical's return on equity of -178.13% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Modular MedicalN/A -178.13% -151.42% Lyra Therapeutics -6,711.39%-295.52%-66.95% Which has more volatility and risk, MODD or LYRA? Modular Medical has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Do insiders and institutionals believe in MODD or LYRA? 27.5% of Modular Medical shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 20.5% of Modular Medical shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate MODD or LYRA? Lyra Therapeutics has a consensus target price of $100.00, indicating a potential upside of 1,351.38%. Given Lyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Modular Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Modular Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lyra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable earnings & valuation, MODD or LYRA? Modular Medical has higher earnings, but lower revenue than Lyra Therapeutics. Modular Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModular MedicalN/AN/A-$18.82M-$0.51-1.44Lyra Therapeutics$1.53M7.21-$93.43M-$60.50-0.11 Does the media prefer MODD or LYRA? In the previous week, Lyra Therapeutics had 3 more articles in the media than Modular Medical. MarketBeat recorded 3 mentions for Lyra Therapeutics and 0 mentions for Modular Medical. Lyra Therapeutics' average media sentiment score of 0.25 beat Modular Medical's score of 0.00 indicating that Lyra Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Modular Medical Neutral Lyra Therapeutics Neutral SummaryLyra Therapeutics beats Modular Medical on 9 of the 15 factors compared between the two stocks. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.84M$2.50B$5.42B$9.56BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-0.1119.6629.9025.14Price / Sales7.21425.09372.1776.15Price / CashN/A165.0335.9458.58Price / Book0.784.198.105.59Net Income-$93.43M$31.61M$3.26B$265.48M7 Day Performance4.71%0.95%0.65%1.22%1 Month Performance-25.51%2.90%2.43%0.39%1 Year Performance-55.22%4.11%27.70%23.47% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics3.3496 of 5 stars$6.89+1.6%$100.00+1,351.4%-55.0%$10.84M$1.53M-0.1150Upcoming EarningsGap UpMODDModular Medical0.469 of 5 stars$0.74+3.4%N/A-52.6%$38.79MN/A-1.4520Upcoming EarningsZYXIZynex2.7765 of 5 stars$1.73+36.4%$4.90+184.1%-81.7%$38.33M$192.35M-1.84770Gap UpHigh Trading VolumeNMTCNeuroOne Medical Technologies1.8404 of 5 stars$0.82+8.6%$1.45+76.2%-1.3%$37.76M$3.45M-3.7420News CoverageUpcoming EarningsShort Interest ↑TMDIFTitan MedicalN/A$0.33-7.1%N/A+747.4%$37.07M$17.63M-0.2650Gap DownNEPHNephros1.5765 of 5 stars$3.24-5.3%$5.00+54.3%+35.0%$36.25M$14.16M46.2930News CoverageEarnings ReportHigh Trading VolumePOCIPrecision Optics0.1811 of 5 stars$4.74+0.6%N/A-19.3%$36.11M$19.10M-5.3380PSTVPlus Therapeutics1.9059 of 5 stars$0.74+26.3%$10.83+1,365.7%-51.4%$35.39M$5.82M-0.2520Upcoming EarningsGap DownHigh Trading VolumePYPDPolyPid2.2593 of 5 stars$3.44+0.9%$11.80+243.0%-8.3%$34.75MN/A-0.8080Upcoming EarningsCOCHEnvoy Medical1.981 of 5 stars$1.43-1.0%$9.25+546.9%-35.8%$30.82M$220K-1.0034Negative NewsUpcoming EarningsVVOSVivos Therapeutics0.4357 of 5 stars$4.76-8.1%$4.82+1.2%+120.5%$30.51M$15.03M-2.75160Upcoming Earnings Related Companies and Tools Related Companies MODD Competitors ZYXI Competitors NMTC Competitors TMDIF Competitors NEPH Competitors POCI Competitors PSTV Competitors PYPD Competitors COCH Competitors VVOS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
